Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
By Colin Kellaher
Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to bolster production of its cell therapies for type-1 diabetes, or T1D.
Vertex on Tuesday said it will receive an exclusive license to TreeFrog's proprietary C-Stem cell-manufacturing technology, which the Boston drugmaker said will enhance its ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
Vertex said it will make a $25 million up-front payment to TreeFrog and an equity investment in the France-based biotech company, which will also be eligible for up to $215 million in milestone payments related to the development of a scaled-up process for fully differentiated, insulin-producing pancreatic islet cells.
Vertex said TreeFrog is also eligible for an additional $540 million in clinical, regulatory and commercial milestones on up to two future products, along with royalties on sales.
Vertex said it will fund all research-and-development costs related to the collaboration and will be responsible for all development and commercialization of its cell therapies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 23, 2024 09:59 ET (13:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy